Spots Global Cancer Trial Database for chop
Every month we try and update this database with for chop cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With Lymphoma | NCT00283439 | Chemotherapy-In... Hodgkin's Lymph... Non-Hodgkin's L... Cancer Oncology Thrombocytopeni... | AMG 531 | 18 Years - | Amgen | |
| Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL) | NCT01839097 | Peripheral T-ce... | Belinostat CHOP | 18 Years - | Acrotech Biopharma Inc. | |
| Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL | NCT00379574 | Lymphoma, Large... Lymphoma, B-Cel... | Bortezomib Cyclophosphamid... Doxorubicin Vincristine Prednisolone Lenograstim | 15 Years - 70 Years | Asan Medical Center | |
| PPI Versus Histamine Antagnists as Adjuvant to Chemotherapy | NCT03647072 | Lymphoma | CHOP CHOP Plus Lanzo... CHOP Plus Famot... | 18 Years - | Tanta University | |
| Safety Study of Darinaparsin in Combination With Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) to Treat Lymphoma | NCT01139359 | Lymphoma | darinaparsin CHOP | 18 Years - | Alaunos Therapeutics | |
| CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell Lymphoma | NCT00893516 | T-cell Lymphoma | CHOP + CD4 CHOP | 18 Years - | Emergent BioSolutions | |
| Targeted Drug Combined With CHOP in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma | NCT04480099 | Peripheral T-ce... | CHOP CHOP+X | 18 Years - | Ruijin Hospital | |
| PK Study on Ready-to-Use Injection (VSLI-RTU) 1 Vial & 3 Vial Formulation Marqibo® in Hematological Malignant Patients | NCT04243434 | Hematologic Dis... | Vincristine Sul... CHOP R-CHOP | 18 Years - | Acrotech Biopharma Inc. | |
| Clinical Study to Compare the Efficacy and Safety of Rituximab Biosimilar HLX01 and Rituximab in Combination With CHOP, in Previously Untreated Subjects With CD20+ DLBCL | NCT02787239 | B-cell Non Hodg... | HLX01 Rituximab CHOP | 18 Years - 80 Years | Shanghai Henlius Biotech | |
| A Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus CHOP With Peripheral T-Cell Lymphoma (PTCL) | NCT02594267 | Peripheral T-Ce... | Pralatrexate In... | 18 Years - | Acrotech Biopharma Inc. | |
| Clinical Trial of Chidamide Combined With CHOP in Peripheral T-cell Lymphoma Patients | NCT02809573 | Peripheral T-ce... | Chidamide cyclophosphamid... adriacin vincristine prednisone | 18 Years - 65 Years | Chipscreen Biosciences, Ltd. | |
| Safety Study of Darinaparsin in Combination With Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) to Treat Lymphoma | NCT01139359 | Lymphoma | darinaparsin CHOP | 18 Years - | Alaunos Therapeutics | |
| A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma | NCT00486759 | B-cell Lymphoma | Bevacizumab Rituximab CHOP Placebo | 18 Years - 79 Years | Hoffmann-La Roche | |
| Phase II Study About Combination CHOP-21, Obinutuzumab and Ibrutinib in Untreated Young High Risk DLBCL Patients. | NCT02670317 | Lymphoma, B-Cel... | Obinutuzumab Ibrutinib CHOP | 18 Years - 60 Years | Fondazione Italiana Linfomi - ETS | |
| Rituximab and Chemotherapy Followed by Ibritumomab Tiuxetan as Treatment for Low Grade Follicular Non-Hodgkin's Lymphoma | NCT00193440 | Non-Hodgkins Ly... | Rituximab CHOP CVP Ibritumomab Tiu... | 18 Years - | SCRI Development Innovations, LLC | |
| Clinical Study to Compare the Efficacy and Safety of Rituximab Biosimilar HLX01 and Rituximab in Combination With CHOP, in Previously Untreated Subjects With CD20+ DLBCL | NCT02787239 | B-cell Non Hodg... | HLX01 Rituximab CHOP | 18 Years - 80 Years | Shanghai Henlius Biotech | |
| SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma | NCT00787527 | Lymphoma | Zolinza (vorino... Cyclophosphamid... Doxorubicin Vincristine Prednisone | 18 Years - | M.D. Anderson Cancer Center | |
| To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL | NCT06072131 | Peripheral T Ce... | Belinostat Inje... Pralatrexate In... CHOP COP | 18 Years - | Acrotech Biopharma Inc. | |
| Compare Efficacy of CHOP Versus Fractionated ICED in Transplant-eligible Patients With Previously Untreated PTCL | NCT02445404 | Peripheral T-ce... | CHOP fractionated IC... | 19 Years - 65 Years | Samsung Medical Center | |
| CHOP-Rituximab Augmented With GM-CSF in Patients With Previously Untreated Diffuse Large B Cell Non-Hodgkin's Lymphoma | NCT00455897 | Lymphoma, Non-H... Lymphoma, B-Cel... Lymphoma, Diffu... | GM-CSF CHOP Rituximab | 18 Years - | Massachusetts General Hospital | |
| Bevacizumab + CHOP-Rituximab in Untreated Mantle Cell Lymphoma | NCT00401817 | Untreated Mantl... | Bevacizumab Rituximab CHOP | 18 Years - | Weill Medical College of Cornell University | |
| Bortezomib and CHOP in Patients With Advanced Stage Aggressive T Cell or Natural Killer (NK)/T Cell Lymphomas | NCT00374699 | Peripheral T-Ce... Non-Hodgkin Lym... | Velcade | 18 Years - 65 Years | Samsung Medical Center | |
| Efficacy of Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With HIV Associated Non-Hodgkin's Lymphoma | NCT00126243 | AIDS Related Ly... | rituximab CHOP | 18 Years - 75 Years | French National Agency for Research on AIDS and Viral Hepatitis | |
| Intensified 1st Cycle Rituximab Plus 8th Cycles of R-CHOP Chemotherapy in Patients With Advanced or Bulky CD20+ Diffuse Large B-cell Lymphoma (DLBCL) | NCT01054781 | Diffuse Large B... | Rituximab | 18 Years - | Samsung Medical Center | |
| PK Study on Ready-to-Use Injection (VSLI-RTU) 1 Vial & 3 Vial Formulation Marqibo® in Hematological Malignant Patients | NCT04243434 | Hematologic Dis... | Vincristine Sul... CHOP R-CHOP | 18 Years - | Acrotech Biopharma Inc. | |
| Alemtuzumab and CHOP Chemotherapy for Aggressive Histological Peripheral T-Cell Lymphomas | NCT00453427 | Peripheral T-ce... | Alemtuzumab (Ca... | 18 Years - | Ontario Clinical Oncology Group (OCOG) | |
| A Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus CHOP With Peripheral T-Cell Lymphoma (PTCL) | NCT02594267 | Peripheral T-Ce... | Pralatrexate In... | 18 Years - | Acrotech Biopharma Inc. | |
| CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas | NCT00323323 | Non-Hodgkin's L... | CHOP Alemtuzumab Plasma Samples | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Phase II Study With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With Gastric Diffuse Large B-Cell Non-Hodgkin's Lymphoma | NCT00204659 | Primary Gastric... | Rituximab + CHO... | 18 Years - | University Hospital Tuebingen | |
| Intensified 1st Cycle Rituximab Plus 8th Cycles of R-CHOP Chemotherapy in Patients With Advanced or Bulky CD20+ Diffuse Large B-cell Lymphoma (DLBCL) | NCT01054781 | Diffuse Large B... | Rituximab | 18 Years - | Samsung Medical Center | |
| Tucidinostat, Azacitidine Combined With CHOP Versus CHOP in Patients With Untreated Peripheral T-cell Lymphoma | NCT05075460 | T-cell Lymphoma | Tucidinostat, A... | 18 Years - 70 Years | Peking Union Medical College Hospital | |
| Efficacy and Safety of Lenalidomide Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma | NCT04922567 | Peripheral T-Ce... Lenalidomide CHOP | Lenalidomide Cyclophosphamid... Doxorubicin Vincristine Prednisone | 18 Years - 75 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| Compare Efficacy of CHOP Versus Fractionated ICED in Transplant-eligible Patients With Previously Untreated PTCL | NCT02445404 | Peripheral T-ce... | CHOP fractionated IC... | 19 Years - 65 Years | Samsung Medical Center | |
| Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma | NCT04002947 | Non-Hodgkin's L... Diffuse Large B... DLBCL NHL | DA-EPOCH Rituximab CHOP Acalabrutinib | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus CHOP With Peripheral T-Cell Lymphoma (PTCL) | NCT02594267 | Peripheral T-Ce... | Pralatrexate In... | 18 Years - | Acrotech Biopharma Inc. | |
| SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma | NCT00365274 | Anaplastic Larg... | Cyclophosphamid... Doxorubicin hyd... vincristine sul... prednisone SGN-30 | 18 Years - | National Cancer Institute (NCI) | |
| Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Waldenstrom's Macroglobulinemia | NCT00060346 | Lymphoma | rituximab cyclophosphamid... Doxorubicin Prednisone Vincristine | 18 Years - | Eastern Cooperative Oncology Group | |
| PPI Versus Histamine Antagnists as Adjuvant to Chemotherapy | NCT03647072 | Lymphoma | CHOP CHOP Plus Lanzo... CHOP Plus Famot... | 18 Years - | Tanta University | |
| A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma | NCT00486759 | B-cell Lymphoma | Bevacizumab Rituximab CHOP Placebo | 18 Years - 79 Years | Hoffmann-La Roche | |
| Compare Efficacy of CHOP Versus Fractionated ICED in Transplant-eligible Patients With Previously Untreated PTCL | NCT02445404 | Peripheral T-ce... | CHOP fractionated IC... | 19 Years - 65 Years | Samsung Medical Center | |
| Lenalidomide in Combination With CHOP in Patients With Untreated PTCL | NCT04423926 | PTCL, NOS AITL ALK- ALCL Phase III-IV AL... EATL | Lenalidomide Cyclophosphamid... Doxorubicin Vincristine Prednisolone | 18 Years - 70 Years | The First Affiliated Hospital with Nanjing Medical University | |
| Efficacy and Safety of Lenalidomide Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma | NCT04922567 | Peripheral T-Ce... Lenalidomide CHOP | Lenalidomide Cyclophosphamid... Doxorubicin Vincristine Prednisone | 18 Years - 75 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell Lymphoma | NCT00893516 | T-cell Lymphoma | CHOP + CD4 CHOP | 18 Years - | Emergent BioSolutions | |
| Bortezomib and CHOP in Patients With Advanced Stage Aggressive T Cell or Natural Killer (NK)/T Cell Lymphomas | NCT00374699 | Peripheral T-Ce... Non-Hodgkin Lym... | Velcade | 18 Years - 65 Years | Samsung Medical Center | |
| Bevacizumab + CHOP-Rituximab in Untreated Mantle Cell Lymphoma | NCT00401817 | Untreated Mantl... | Bevacizumab Rituximab CHOP | 18 Years - | Weill Medical College of Cornell University | |
| Rituximab and Chemotherapy Followed by Ibritumomab Tiuxetan as Treatment for Low Grade Follicular Non-Hodgkin's Lymphoma | NCT00193440 | Non-Hodgkins Ly... | Rituximab CHOP CVP Ibritumomab Tiu... | 18 Years - | SCRI Development Innovations, LLC | |
| Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma | NCT01796002 | Peripheral T-ce... | Romidepsin + CH... CHOP | 18 Years - 80 Years | The Lymphoma Academic Research Organisation | |
| Efficacy of Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With HIV Associated Non-Hodgkin's Lymphoma | NCT00126243 | AIDS Related Ly... | rituximab CHOP | 18 Years - 75 Years | French National Agency for Research on AIDS and Viral Hepatitis | |
| A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With Lymphoma | NCT00283439 | Chemotherapy-In... Hodgkin's Lymph... Non-Hodgkin's L... Cancer Oncology Thrombocytopeni... | AMG 531 | 18 Years - | Amgen | |
| Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL) | NCT04745832 | Follicular Lymp... Non Hodgkin Lym... Marginal Zone L... | Zandelisib Rituximab Bendamustine CHOP | 18 Years - | MEI Pharma, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
